S aphenous vein graft (SVG) atherosclerosis after coronary artery bypass grafting (CABG) remains the primary cause of late graft failure, with SVG obstruction rates as high as 50% having been reported 10 years post-CABG. . Patients were randomized (1:1) to DES implantation (SVG-DES) or medical treatment (SVG-MT) of the target SVG lesion. The primary efficacy outcome was the first occurrence of MACE defined as the composite of cardiac death, myocardial infarction, or coronary revascularization related to the target SVG during the duration of follow-up (minimum of 2 years). Secondary efficacy outcomes included MACE related to the target SVG lesion and overall MACE. A total of 125 patients (mean age 70±9 years, 87% men) were included, with a mean time from coronary artery bypass graft of 12±5 years. Sixty and 65 patients were allocated to the SVG-DES and SVG-MT groups, respectively. There were no events related to the target SVG at 30 days. After a median follow-up of 3.4 (interquartile range: 2.8-3.9) years, the MACE rate related to the target SVG was not significantly different in the 2 groups (SVG-DES: 15.0%, SVG-MT: 20.0%; hazard ratio, 0.65; 95% confidence interval, 0. 
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Drug Eluting Stents) showed that stenting intermediate nonobstructive SVG lesions with a drug-eluting stent (DES) was associated with a lower rate of SVG disease progression as evaluated by angiography and intravascular ultrasound at 1-year follow-up. 9 Also, a tendency toward a lower rate of cardiovascular events related to the SVG was observed at 1-and 5-year follow-up in those patients allocated to SVG plaque sealing with a DES. 9, 10 These data provided the rationale for designing the prospective randomized VELETI II trial (Sealing Moderate Coronary Saphenous Vein Graft Lesions With Paclitaxel-Eluting Stents), with the objective of assessing the efficacy of stenting intermediate nonobstructive SVG lesions with DES (paclitaxel-or everolimus-eluting stents) in reducing the first occurrence of the composite of cardiac death, myocardial infarction (MI), or repeat revascularization related to the target SVG during the duration of follow-up (minimum of 2 years).
Methods

Study Design and Patients
This was a randomized clinical trial conducted in 16 centers in Canada (see Data Supplement), and it was approved by the local Ethics Committee of each participating center. All patients provided signed written informed consent for participating in the trial. An independent data and safety monitoring board was responsible for the monitoring of patient safety.
The study included patients aged ≥18 years with previous CABG, including at least 1 SVG and a clinical indication for coronary SVG angiography. Patients with at least 1 intermediate SVG lesion (30%-60% diameter stenosis by visual estimation) that was not the culprit lesion responsible for the clinical syndrome of the patient were eligible. The main exclusion criteria were SVG <1-year-old, SVG diameter <2.5 mm or >5 mm, presence of more than 2 intermediate SVG lesions in a single SVG or significant diffuse SVG disease defined as angiographic disease covering more than half of the length of the SVG, presence of more than 2 SVGs with intermediate SVG lesions, SVG lesion located at the distal anastomosis, short lesion (<5 mm long) limited strictly to the ostium of the SVG with no extension toward the proximal segment of the SVG, presence of thrombus or ulceration, unsuccessful angioplasty (residual stenosis >30% or Thrombolysis in Myocardial Infarction flow <3) of any other lesion treated during the same procedure (culprit lesions responsible for the qualifying coronary syndrome were treated before patient randomization), cardiogenic shock, renal insufficiency with creatinine >200 μmol/L, contraindication to aspirin or thienopyridine/ticagrelor treatment, allergy to paclitaxel or everolimus, comorbid condition with a limiting life-expectancy (<2 years), and need for chronic anticoagulant therapy. A quantitative coronary angiography analysis of the SVG lesions was performed offline with the Pie Medical CAAS system (Maastricht, The Netherlands).
Patients were randomized (1:1) to coronary angioplasty of the target SVG lesion(s) with DES implantation versus medical treatment (MT). Random block sizes were used to conceal treatment allocation from the patients, and randomization was stratified by clinical center. All patients were prescribed aspirin (at least 81 mg/d) indefinitely, and all those who received DES were prescribed P2Y12 inhibitor (clopidogrel 75 mg/d or pasugrel 10 mg/d) or ticagrelor (90 mg bid) for at least 1 year.
The SVG target lesion angioplasty was performed using standard techniques with either paclitaxel-eluting stents (Taxus, Taxus Element or Ion stents; Boston Scientific Corp, Natick, MA) or everolimuseluting stents (Promus Element stent; Boston Scientific Corp, Natick, MA). The use of a filter wire EX (Boston Scientific Corp) distal to the target lesion during the angioplasty procedure was recommended if technically feasible.
Clinical follow-up took place by telephone or clinic visits at 30 days, 180 days, 1 year, and 2 years after randomization and yearly thereafter until the common study end date. The occurrence of adverse events, cardiac symptoms, and medication compliance were assessed at each follow-up visit. The events were adjudicated by an independent event adjudication committee.
Efficacy Outcomes
The primary efficacy outcome was the first occurrence of major adverse cardiac events (MACEs) defined as the composite of cardiac death, MI, or coronary revascularization related to the target SVG during the duration of follow-up. Secondary efficacy outcomes were the occurrence of cardiac death, MI, or revascularization overall (irrespective if related or not to the SVG) or related to the target SVG lesion; any hospitalization due to an acute coronary syndrome related to the target SVG; major bleeding complications defined according to the REPLACE-2 criteria (Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events-2) 11 ; and stent thrombosis defined according to the Academic Research Consortium criteria. 12 Periprocedural MI was defined as any postprocedural increase in creatine kinase-myocardial band (CK-MB) levels ≥3× the upper limit of normal. In case of elevated cardiac biomarkers before the procedure, MI was defined as any CK-MB value postprocedure ≥50% compared with preprocedural values.
WHAT IS KNOWN
• Intermediate nonobstructive saphenous vein graft lesions have been associated with rapid disease progression leading to a high rate of clinical events.
WHAT THE STUDY ADDS
• In this small randomized trial, sealing intermediate nonobstructive saphenous vein graft lesions with drug-eluting stents was safe but was not associated with a significant reduction of cardiac events at 3-year follow-up. The only major protocol amendment (January 2012) was the addition of everolimus-eluting stent as DES (in addition to placlitaxeleluting stents).
Statistical Analyses
On the basis of the results of the VELETI trial, 9 we estimated a cumulative MACE (cardiac death, MI, or revascularization) rate related to the target SVG of 22% at 2-year follow-up in the group of patients randomized to MT compared with a 12% MACE rate in the group randomized to SVG angioplasty (relative risk reduction: 45%). A sample size of 218 patients per group was required to obtain 80% power to detect differences between groups at 0.05 level of significance. To compensate for drop-out or patients lost to follow-up (<5%), the sample size was increased to 450 patients (225 patients per group). Patients were enrolled from February 2011 to August 2013, and the last patient follow-up was completed in January 2016. The trial was prematurely stopped because of slow patient enrollment after the inclusion of 125 patients.
All randomized patients were included in the main analyses. Patients were included in the treatment group to which they were Table 2 Values are reported as n (%). CI indicates confidence interval; DES, drug-eluting stents; HR, hazard ratio; MACE, major adverse cardiac events; MT, medical treatment; and SVG, saphenous vein graft. Plaque Sealing and Saphenous Vein Grafts originally allocated by the IVRS (intent-to-treat analysis). Additional analyses of the patients who finally received the allocated treatment (as treated) were also performed for the primary end point and the key secondary end points. For the primary outcome, the relative efficacy of SVG stent implantation versus MT was assessed by a comparison of the survival curves for the 2 treatments using the log-rank statistic (primary test of treatment effect). Treatment effect was also analyzed using a Cox proportional hazard model. Similar analyses were performed for the secondary end points. Statistical significance was claimed if the computed 2-sided P value for the primary and secondary end points was ≤0.05. Considering that the trial was prematurely stopped (at 28% of the planned sample size), all results should be considered as exploratory. The data were analyzed using SAS statistical software version 9.4 (SAS Institute Inc, Cary, NC).
Results
Patient flow through the trial is shown in Figure 1 . A total of 125 patients with previous CABG including SVG with a clinical indication of coronary angiography fulfilled the clinical and angiographic eligibility criteria and provided informed consent. Sixty patients were randomized to SVG target lesion angioplasty with DES implantation (SVG-DES) and 65 patients to MT (SVG-MT). A total of 5 patients in the SVG-DES group did not finally receive the allocated treatment, and all patients in the SVG-MT group received the allocated treatment. No patient was lost to follow-up.
The baseline clinical and angiographic characteristics of the study population according to treatment allocation are shown in Table 1 . The mean age of the study population was 70±9 years and 87% were male. The median time from CABG was 12 (interquartile range: 8-16) years. A total of 117 patients (94%) were receiving statin therapy, with a mean lowdensity lipoprotein of 66±27 mg/dL at baseline.
Among the 125 patients enrolled, there were a total of 142 intermediate lesions documented in 126 SVGs, with a mean percent diameter stenosis of 51±21% by visual estimation (42±13% by quantitative coronary angiography analysis). No lesion exhibited complex (thrombus and ulceration) features. Among the 60 patients in the SVG-DES group, 49 paclitaxel-eluting stents and 14 everolimus-eluting stents were implanted. A filterwire during SVG-PCI was used in 21 (35.0%) patients. There were no complications related to the PCI of the intermediate SVG lesion. There were no events at 30 days related to the target SVG.
After a mean follow-up of 3.4 (interquartile range: 2.8-3.9) years, a total of 22 patients (17.6%) had at least 1 MACE related to the target SVG. A total of 11 patients had an MI related to the SVG, and 20 patients underwent target SVG revascularization. The primary and secondary efficacy end points for the study population are shown in Table 2 . There were no significant differences in the rate of MACE between groups (15.0%, 6.3 per 100 patient-years in the SVG-DES group versus 20.0%, 9.2 per 100 patient-years in the SVG-MT group; hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.23-1.53; P=0.33). The rates of target SVG MI or revascularization were also not significantly different between groups. There were no cardiac deaths related to the target SVG. The cumulative incidence of MACE related to the target SVG according to the randomization group are shown in Figure 2 . Among the 6 MI events related to the target SVG in the SVG-DES group, 2 were because of stent restenosis, 1 was related to stent thrombosis (at 31 months of follow-up), and 3 were not related to the target SVG lesion (SVG disease progression in unstented segments; Figure 3 ). The 5 MI events related to the target SVG in the SVG-MT group were related to the progression of the target SVG lesion (Figure 3 ). Among the 9 target SVG revascularization events in the SVG-DES group, 6 were related to stent restenosis (4 of them occurring late, ≥1 year, after PCI) and 3 were related to SVG disease progression of unstented segments (Figure 3 ). Among the 11 target SVG revascularization events in the SVG-MT group, 9 were related and 2 were unrelated to the target SVG lesion. The rate of hospitalization because of an acute coronary syndrome related to the target SVG was not significantly different between groups (SVG-DES: 15.0%, 4.6 per 100 patient-years; SVG-MT: 10.8%, 3.4 per 100 patientyears; HR, 1.33; CI, 0.49-3.56; P=0.58).
The incidence of MACE related to the target SVG lesion according to treatment allocation is shown in Table 2 and Figure 4 . There were no significant differences between groups in the rate of MACE related to the target SVG lesion (SVG-DES: 10%, 3.1 per 100 patient-years, SVG-MT: 16.9%, 5.7 per 100 patient-years; HR, 0.53; 95% CI, 0.20-1.43; P=0.21). The rates of MI or revascularization related to the target SVG lesion were not significantly different between groups.
The rates of global MACE (irrespective if related or not to the target SVG) according to the allocated treatment are shown in Table 2 and Figure 5 . A total of 51 patients (40.8%) had at least 1 MACE during the study period, with no significant differences between groups (SVG-DES group: 36.7%, 12.9 per 100 patientyears; SVG-MT group: 44.6%, 17.8 per 100 patient-years; HR, 0.73; 95% CI, 0.42-1.27; P=0.26). The rates of global cardiac death, MI, or vessel revascularization were not significantly different between groups. There were no significant differences between groups in the rate of major bleeding complications (SVG-DES: 1.7%, 0.49 per 100 patient-years; SVG-MT: 1.5%, 0.47 per 100 patient-years; HR, 1.06; CI, 0.07-16.9; P=0.97).
The rates of MACEs according to the allocated treatment in those patients who actually received the allocated treatment (as treated population) are shown in Table 3 . There were no significant differences between groups in the rate of MACE during the duration of follow-up. It is well known that patients with previous CABG having a cardiac event several years after the operation exhibit a high rate of recurrent events within the months after this first episode. 13 The patients included in the VELETI II trial had a cardiac event requiring coronary angiography at a median time of 12 years after CABG, and close to half of these patients had a recurrent event in the following 3 years. Of note, more than half of these recurrent events were related to an SVG exhibiting an intermediate nonobstructive lesion at the time of the first coronary angiography.
The rapid progression of intermediate nonobstructive SVG lesions leading to a high rate of cardiovascular events has been shown in multiple studies. [2] [3] [4] [5] [6] [7] [8] [9] [10] The incidence of cardiac events related to the progression of intermediate SVG lesions was 19% at 1-year follow-up and increased to 33% at 5-year follow-up in the pilot single-center VELETI trial. 9, 10 Of note, all cases of SVG failure were related to SVG disease progression at the level of the intermediate SVG lesion and led to an acute coronary syndrome in most cases. Consistent with these results, the MACE rate related to target SVG failure in the VELETI II trial was 20%, and the events were related to the progression of the intermediate SVG lesion in close to 90% of the cases, confirming the major impact of such lesions on the high event rate in these patients. Also in accordance with previous studies, SVG disease progression led to an acute coronary syndrome in most patients and MI accounted for about one third of the events. Importantly, this rapid progression occurred despite appropriate statin therapy in most patients, with mean low-density lipoprotein levels of <70 mg/dL.
The concept of mechanical plaque sealing of nonobstructive coronary lesions for preventing cardiovascular events has been around since the introduction of stent technology in interventional cardiology.
14,15 However, the low event 16, 17 The accelerated process of atherosclerosis progression observed in intermediate SVG lesions would, therefore, represent a much better model for evaluating a mechanical plaque sealing strategy. However, SVG stenting has been associated with a high rate of periprocedural events, 18 generating concerns about the safety of implementing mechanical plaque sealing in SVGs. Importantly, previous studies showed that the most periprocedural events during SVG-PCI occurred in those lesions with the highest plaque burden or with complex features, such as thrombus or ulceration. [19] [20] [21] In contrast, the VELETI trial 9 showed a low rate of periprocedural events associated with stenting intermediate SVG lesions, and the present trial further confirmed the safety of this strategy, with no events at 30 days related to intermediate SVG lesion sealing with DES.
Despite the absence of safety issues, sealing intermediate lesions in old SVGs with DES failed to significantly reduce cardiovascular events at a median follow-up of 3 years. Apart from sample size issues related to the premature ending of the trial, the event rate related to SVG failure in patients receiving DES (15%) was slightly higher than expected. This was partially because of the 10% SVG repeat revascularization rate secondary to DES clinical restenosis (mainly ≥1-year follow-up) in most cases. The pilot VELETI trial 9 showed an absence of angiographic restenosis at 1-year follow-up in patients who received paclitaxel-eluting stents for sealing intermediate SVG lesions. However, late (5 years) restenosis occurred in 13% of patients, 10 significantly reducing the initial clinical benefit that had been observed at 1-year followup. In accordance with these results, the event rate associated with the SVG plaque sealing strategy in VELETI II was as low as 3% at 2-year follow-up (versus 16% in the MT group). However, the occurrence of several cases of late (>2 years) restenosis significantly reduced the marked early beneficial effect observed with the sealing strategy. First-and secondgeneration DES have been shown to be superior to bare-metal stents with respect to angiographic and clinical restenosis after SVG-PCI. [22] [23] [24] However, the late restenosis phenomenon after Plaque Sealing and Saphenous Vein Grafts SVG stenting has been described with the use of first-generation DES, 25, 26 and it is unclear at this time whether this may also occur with the use of newer-generation DES. Reducing late stent restenosis seems to be a key factor in maintaining the potential initial clinical benefits of intermediate SVG lesions plaque sealing.
In addition to late restenosis, the progression of SVG disease in unstented segments was responsible for the clinical events in one third of the patients. Lipid-lowering therapy has been proven to be the only medical therapy capable of retarding SVG disease progression, 27 and the vast majority of patients included in the VELETI-II trial were receiving statin therapy, leading to mean low-density lipoprotein levels <70 mg/dL. Further reductions in low-density lipoprotein levels may be embraced as a further step in trying to prevent SVG atherosclerosis progression in old SVGs with intermediate lesions. A pilot study using niacin with the objective of increasing high-density lipoprotein levels failed to reduce SVG disease progression in patients with intermediate SVG lesions.
28 Table 3 Values are reported as n (%). CI indicates confidence interval; DES, drug-eluting stents; HR, hazard ratio; MACE, major adverse cardiac events; MT, medical treatment; and SVG, saphenous vein graft. Plaque Sealing and Saphenous Vein Grafts
Limitations
The VELETI II trial was stopped prematurely because of slow enrollment rate. This prevents us from providing definite conclusions about the primary efficacy outcome of the study, and the results should, therefore, be interpreted as hypothesis generating. The main reasons for the slow enrollment rate were primarily angiographic (the SVGs of the majority of patients screened were either patent with no lesion or occluded) and secondarily clinical (mainly related to the need for anticoagulation therapy in patients with atrial fibrillation, which was an exclusion criterion). However, the study provides important clues about the possible limitations of a mechanical sealing strategy in SVGs and underscores the difficulties of enrolling patients with intermediate SVG lesions in the current era. This should be taken into account in the design of future studies in this field. No systematic screening log and no blinding process were implemented in this trial. Intravascular imaging techniques have demonstrated higher efficacy in determining plaque vulnerability than coronary angiography. 29 No intravascular imaging examinations were used in this trial, and future studies may explore the usefulness of these techniques for evaluating plaque vulnerability in SVGs. Finally, first-generation DES (paclitaxeleluting stents), no longer used in current clinical practice, were used in most patients in the SVG-DES group.
In conclusion, patients with intermediate nonobstructive lesions in old SVGs are at high risk of SVG disease progression leading to MACE at mid-term follow-up. Sealing such lesions with DES (mainly paclitaxel-eluting stents) was safe but failed to significantly reduce cardiac events after a median follow-up of ≈3 years. Future studies in the area of the mechanical plaque sealing of SVGs should focus on reducing late restenosis to demonstrate the superiority of this approach over optimal MT. Also, more aggressive lipid-lowering therapies may be evaluated to reduce SVG atherosclerosis progression in this high-risk population.
